NCT07323329 Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
| NCT ID | NCT07323329 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Beni-Suef University |
| Condition | Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 165 participants |
| Start Date | 2025-10-10 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 165 participants in total. It began in 2025-10-10 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Eligibility Criteria
Inclusion Criteria: At least two of the following three criteria had to be present after maximal stimulation: 1. Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR). 2. ≤3 oocytes with a conventional stimulation protocol). 3. An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\]. Exclusion Criteria: 1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction. 2. Any pelvic pathology such as hydrosalpinx, uterine anomaly. 3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
Frequently Asked Questions
Who can join the NCT07323329 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07323329 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07323329 currently recruiting?
Yes, NCT07323329 is actively recruiting participants. Visit ClinicalTrials.gov or contact Beni-Suef University to inquire about joining.
Where is the NCT07323329 trial being conducted?
This trial is being conducted at Banī Suwayf, Egypt.
Who is sponsoring the NCT07323329 clinical trial?
NCT07323329 is sponsored by Beni-Suef University. The trial plans to enroll 165 participants.